Revenue, R&D and Biotech’s Future

Special purpose acquisition companies (SPACs) nearly went the way of the dinosaur after the 2007–2008 financial crisis. However, COVID-19 has seemingly brought them back to life as pandemic-driven market volatility continues to disrupt and complicate the traditional path to an IPO.

In the push to innovate patient care and improve health outcomes, biotech IPOs were on a hot streak in 2018. Endpoints reports that 33 firms went public in the first half of 2018, raising a total of $3.25 billion and already outpacing the total raised in 2017.

Nothing returns to normal without life sciences. Tasked with charting a sustainable road to recovery for both the industry and the global economy at large, life sciences CFOs feel confident about the pivots they made in crisis and are optimistic for growth in 2021.